Ultra-processed baby foods ‘set children up for lifetime of obesity,' experts warn
A study by researchers at the University of Leeds found that one in three baby food products filling the aisles are classed as ultra-processed foods (UPF), which have been linked to long-term health damage.
Researchers have also warned parents over 'misleading' packaging which promotes natural ingredients in a food product that is industrially produced.
The team analysed 600 baby food items from major brands and found that a staggering 87 per cent of baby snacks and 79 per cent of baby cereals are classed as UPFs. This means they were made using industrial techniques, with ingredients not typically found in home cooking.
They also found 'troubling trends' in popular snacks marketed at infants, including 'melty' puffed snacks and fruit-based chews and bars.
The study's authors are now calling on the government to introduce tougher regulations on UPFs, saying the foods on offer 'bear little resemblance to the kind of food young children should be growing up on'.
Dr Diane Threapleton, lead researcher and paediatric nutrition expert at the University of Leeds said: 'We're seeing highly processed snacks, sweets, cereals - even meals dominating the baby aisle. These are often marketed as healthy, organic, or with 'no added sugar' claims, but they contain ingredients and undergo processing that bear little resemblance to the kind of food young children should be growing up on.
'These products are setting up babies to crave ultra-processed, overly sweet foods from the very start. There's a real opportunity now for the Government to show it's serious about raising a healthier generation. The current state of the baby food aisle is unacceptable, and it must no longer be ignored.'
Their work is backed by the Obesity Health Alliance (OHA), who said the government needs to act 'urgently' to clamp down on the sale of sugary snacks with 'misleading' labelling.
The director of the OHA, Katharine Jenner, said: 'The Government's 10-Year Health Plan talks of a moonshot to end obesity, but we'll never get off the launchpad unless we close the gap in our early years. A healthy life starts from the very beginning and right now, we're feeding our babies and toddlers ultra-processed foods that undermine their development and long-term health.
'The baby food aisle is flooded with sugary, ultra-processed snacks that set children up for a lifetime of poor eating habits, obesity, and tooth decay. With the UK in the grip of an oral health crisis, we urgently need government to limit baby food companies from selling high sugar foods with misleading labelling.'
She added: 'These products undermine the best intentions of parents and carers, who want to put their child's health first.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
30 minutes ago
- Medscape
Body Composition, Not Just BMI, Matters in Psoriatic Disease
BOGOTÁ, Colombia — While obesity has been studied extensively in psoriasis and psoriatic arthritis (PsA), little is known about the role of body composition, or the specific location of fat deposition in and around organs and muscle, in these diseases. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, two groups of researchers working with MRI and clinical data from the UK Biobank presented detailed findings that shed light on how different body composition profiles might influence or be influenced by psoriatic disease. Visceral, Liver, and Muscle Fat Predict Disease In a poster, Rheumatologist Jean-Guillaume Letarouilly, MD, PhD, of Lille University, Lille, France, and Oxford University, Oxford, England, showed results from a cross-sectional study of 841 patients with psoriasis, 125 patients with PsA, and about 34,000 nonpsoriatic control individuals. Patients across groups had a mean age of 64 years, were nearly all White, approximately half were women, and only a minority (17%-22% across groups) had a BMI ≥ 30. All patients underwent abdominal MRI scan, and participants with psoriasis or PsA were identified by self-report and primary care and hospital records. In multivariate models, Letarouilly and his colleagues found that patients diagnosed with psoriasis tended to have significantly lower muscle volume, higher liver fat, higher visceral fat, higher muscle fat infiltration, and higher total abdominal fat than control individuals without psoriasis. Patients diagnosed with PsA, meanwhile, tended to have significantly elevated liver fat, higher muscle fat infiltration, and higher abdominal fat (but not visceral fat) than control individuals without PsA. The results were suggestive of 'a potential impact of the inflammatory burden of the psoriatic disease on the body composition,' the investigators concluded. In an interview at the meeting, Letarouilly cautioned that his findings 'are for the moment just descriptive. What we need to do now is determine in a longitudinal way whether these body composition changes appear before the disease itself and what role these different types of body fat play in the [pathologic] process.' Body Composition Profiles Predict Comorbidities At the same meeting, Lyn Ferguson, MBChB, PhD, of the University of Glasgow, Glasgow, Scotland, presented results from a different body composition study using UK Biobank data. Ferguson compared results for 236 patients with psoriasis and 1180 control individuals matched for age (mean of about 66 years), sex (about 51% women), and BMI (about 27) — all variables that can affect body fat distribution. She also identified 61 patients with PsA and 305 matched control individuals, both of whom had a mean age of about 63 years, 49% were women, and BMI of about 27. None of the control individuals had metabolic or cardiovascular disease at the time of their baseline scans. Ferguson aimed to determine not only whether people with psoriasis and PsA are more likely to have certain body composition profiles but also whether the same measures of body composition — liver fat, visceral fat, and muscle quality — could also predict diabetes and coronary heart disease in these patients. Ferguson found that people with psoriasis had significantly more fat around the organs (visceral), in the liver, and in muscle, whereas people with PsA had significantly more fat in the liver and muscle than age-, sex-, and BMI-matched control individuals. These body composition profiles were significantly associated with greater propensity to type 2 diabetes. 'We know from the clinic that patients with psoriatic disease have a greater prevalence of diabetes,' Ferguson said in an interview at the meeting. 'This could be in part related to the fat distribution pattern in psoriasis and PsA.' The Surprising Importance of Muscle Ferguson noted that about half of people with psoriasis or PsA had either low muscle volume, high muscle fat, or both — a state known as adverse muscle composition. In individuals with psoriatic disease, adverse muscle composition was associated with over double the propensity to coronary heart disease and three times the propensity to type 2 diabetes compared with a normal muscle composition. Ferguson said a provocative finding from her study was that poor muscle quality was also associated with more than double the risk for new-onset psoriasis (adjusted hazard ratio, 2.12; 95% CI, 1.29-3.50). 'Having more fat stored in the muscle and lower muscle volume appears to be associated with greater risk of developing psoriasis. Whether this may relate to muscle fat being potentially more pro-inflammatory, or whether immune-metabolic dysregulation is already present and contributing to more fat in the muscle and muscle loss, is unknown and warrants further study.' At a meeting intensely focused on the potential benefits of GLP-1 receptor agonists (RAs) in psoriatic disease, both Ferguson and Letarouilly said the muscle-quality findings were of special concern to them as physicians. 'It's really important that people stay physically active to maintain muscle quality, especially if you're losing a lot of weight' because of using GLP-1 RAs, Ferguson said. With the profound weight loss from this drug class, 'a significant amount of weight loss could be muscle. And we've identified a group that has lower thigh muscle volume. That's something we have to watch.' Letarouilly added that stopping GLP-1 drugs has been reported to result in sarcopenic obesity, or concurrent muscle loss and fat gain. 'That's why it is important to advise people to do more exercise,' he said, adding that maintaining bone health is another, related concern. 'We already see this with obesity surgery. With GLP-1s, we would need to monitor patients in the same way.'
Medscape
30 minutes ago
- Medscape
Enterosorbent Gel Shows Efficacy in IBS
TOPLINE: Silicolgel, a colloidal silicic acid enterosorbent, was generally safe and well tolerated, and it significantly reduced symptom severity in adults with irritable bowel syndrome, with efficacy being observed in both patients with predominant diarrhoea (IBS-D) and those with mixed bowel habits (IBS-M). METHODOLOGY: Researchers conducted a randomised controlled trial to assess the efficacy, safety, and tolerability of silicolgel in patients with IBS-D and IBS-M. They included 120 adults (mean age, 36.9 years; 66% women) with IBS-D or IBS-M across four regional health centres in Ukraine between March 15, 2023, and August 31, 2023, with a score on the IBS Severity Scoring System (IBS-SSS) of 100-400 points. Patients were randomly assigned to receive either 15 mL of silicolgel (n = 60) or placebo (n = 60) three times daily for 4 weeks, followed by a 4-week no-medication observation phase to assess the return of symptoms. The primary outcome was a reduction in IBS-SSS scores by ≥ 50 points after 4 weeks of treatment, indicating a clinically meaningful improvement in symptoms. Patients used daily diaries to track bowel habits, IBS symptoms (including abdominal pain and bloating), and quality of life. TAKEAWAY: After 4 weeks, the proportion of patients achieving at least a 50-point reduction in the IBS-SSS score was significantly higher in the silicolgel group than in the placebo group (91.67% vs 20%; relative risk [RR], 4.58; P < .0001). The silicolgel group showed a significantly greater decrease in the mean IBS-SSS score, from 255.62 at baseline to 92.75 after 4 weeks, than the placebo group that showed a change from 254.42 at baseline to 257.58 after 4 weeks (P < .001). Among patients with IBS-D and IBS-M, those on silicolgel vs placebo achieved the primary outcome (RR, 4.77 and 4.44, respectively; P < .0001 for both). Significant reductions in mean severity scores were noted for IBS symptoms from baseline to week 4 with silicolgel. All adverse events were mild and non-serious, noted at one site, and found unrelated to treatment, with no treatment discontinuations observed. IN PRACTICE: "Silicolgel is a widely available and affordable enterosorbent treatment, providing safe and effective relief of symptoms in patients with IBS-D and IBS-M. Based on these findings, its use should be considered more widely for frontline therapy of IBS-D and IBS-M," the authors of the study wrote. SOURCE: This study was led by O. Kuzminska, Chernivtsi Hospital of Emergency Medical Care, Chernivtsi, Ukraine. It was published online on July 25, 2025, in Neurogastroenterology & Motility. LIMITATIONS: Silicolgel is not absorbed and works locally in the gut, beginning to exert its effect immediately. Thickeners could not be used in the placebo because they affect the gut, so the viscosity of the placebo was a white, watery solution. Additionally, the treatment was limited to 28 days as silicolgel's licence permits a continuous dosing period of not more than 4 weeks. DISCLOSURES: This study was supported by FW Medical Ltd, the owner of silicolgel, and Delta Medical LLC, the distributor of silicolgel in Ukraine. They had no direct involvement in the study. One author reported being a consultant for the owner company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
30 minutes ago
- Medscape
SSRIs and SNRIs Boost Clozapine Treatment Response
TOPLINE: Standard doses of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) reduced the risk for relapse when added to clozapine in treatment-resistant schizophrenia, unlike other antidepressants, according to a new study. Sertraline, duloxetine, and escitalopram were particularly effective, and high-dose antidepressant use increased both psychiatric and somatic hospital admission risks. METHODOLOGY: Researchers analysed and then meta-analysed data from two register-based, nationwide cohort studies in Finland (1996-2017) and Sweden (2006-2023) and included 23,206 patients with schizophrenia (mean age, 41.3 years; 9531 women) who were followed up from first clozapine use until death or the end of data linkage. This study had a within-individual cohort design in which each person served as their own control and compared clozapine augmentation with specific antidepressants against clozapine use alone. Researchers categorised antidepressant use into four dose categories: low (< 0.6 defined daily doses [DDDs] per day), standard (0.6 to < 1.1 DDDs per day), medium-high (1.1 to < 2.1 DDDs per day), and high (≥ 2.1 DDDs per day), with specific milligrams per day ranges for each medication. The primary outcome was schizophrenia relapse, defined as hospital admission with psychotic disorder; the secondary outcome was somatic hospital admission. The mean follow-up duration was 12.1 years for the Finnish cohort and 11.4 years for the Swedish cohort. TAKEAWAY: A total of 65.8% of patients in the Finnish cohort and 51.0% in the Swedish cohort had a relapse during follow-up. Additionally, 52.6% of patients in the Finnish cohort and 41.2% in the Swedish cohort experienced hospital admission because of somatic reasons during follow-up. The lowest risk for relapse was observed with sertraline (adjusted hazard ratio [aHR], 0.76), followed by duloxetine (aHR, 0.78) and escitalopram (aHR, 0.85; P < .001 for all). Antidepressants other than SSRIs and SNRIs were associated with an increased risk for relapse without achieving statistical significance. Standard doses showed optimal effectiveness, with sertraline 30-54 mg/d (aHR, 0.49; 95% CI, 0.27-0.89), escitalopram 6-10 mg/d (aHR, 0.57; 95% CI, 0.37-0.88), and duloxetine 18-32 mg/d (aHR, 0.59; 95% CI, 0.46-0.75) showing the lowest risk for relapse. Augmentation with antidepressants was not associated with an increased risk for somatic hospital admission at low or standard doses; however, high-dose use was linked to elevated risks for both relapse and somatic hospital admission. IN PRACTICE: "[The study] findings support the use of SSRIs and SNRIs as viable augmentation strategies for clozapine-treated patients with schizophrenia, particularly at standard doses," the authors wrote. "The same finding was not observed with other, non-SSRI and non-SNRI antidepressants," they added. "The findings have important clinical implications, emphasising the potential utility of antidepressant augmentation in specific subgroups of patients with TRS [treatment-resistant schizophrenia], such as those with persistent negative symptoms, comorbid depression, or suicidal ideation. Given the increased risks associated with high-dose antidepressant use, clinicians should carefully balance the potential benefits with the risk of adverse outcomes," they concluded. SOURCE: This study was led by Heidi Taipale, PhD, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. It was published online in the August 2025 issue of The Lancet Psychiatry. LIMITATIONS: This study was limited by its observational design, the lack of randomisation, and the low number of users for some exposures. This study lacked information on why antidepressants were started or stopped, symptom severity fluctuations, social support or non-pharmacologic interventions, and confirmation of treatment resistance. Additionally, dose categorisation on the basis of DDDs was not optimal for some drugs. Schizophrenia relapse was broadly defined as hospital admission with psychotic disorder without symptom specificity, and major depressive disorder was rarely recorded. Furthermore, the findings were limited to long-term risks in low-cost healthcare settings, and people with lived experience were not involved. DISCLOSURES: This study received funding from the Sigrid Jusélius Foundation and the Finnish Ministry of Social Affairs and Health. This project used data from the REWHARD consortium supported by the Swedish Research Council. Several authors reported having financial ties with various sources including pharmaceutical companies. Details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
